These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9248972)
21. [Differential use of cephalosporins in treatment of upper and lower respiratory tract infections]. Dvoretskiĭ LI; Omel'ianovskiĭ VV Antibiot Khimioter; 1998; 43(6):24-8. PubMed ID: 9644531 [No Abstract] [Full Text] [Related]
22. [Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections]. Hernández-Martin J; Romá E; Salavert M; Doménech L; Poveda JL Rev Esp Quimioter; 2006 Sep; 19(3):231-46. PubMed ID: 17099791 [TBL] [Abstract][Full Text] [Related]
23. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Plouffe JF Clin Infect Dis; 2000 Sep; 31 Suppl 4():S144-9. PubMed ID: 11017864 [TBL] [Abstract][Full Text] [Related]
24. Cefotaxime use in pediatric infections. Dajani AS Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022 [TBL] [Abstract][Full Text] [Related]
25. The choice of antibacterial drugs. Med Lett Drugs Ther; 1999 Oct; 41(1064):95-104. PubMed ID: 10548955 [No Abstract] [Full Text] [Related]
26. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284 [TBL] [Abstract][Full Text] [Related]
27. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections. Boccazzi A; Tonelli P; Bellosta C; Careddu P Diagn Microbiol Infect Dis; 1998 Dec; 32(4):265-72. PubMed ID: 9934543 [TBL] [Abstract][Full Text] [Related]
28. Emergence of two populations of methicillin-resistant Staphylococcus aureus with distinct epidemiological, clinical and biological features, isolated from patients with community-acquired skin infections. Del Giudice P; Blanc V; Durupt F; Bes M; Martinez JP; Counillon E; Lina G; Vandenesch F; Etienne J Br J Dermatol; 2006 Jan; 154(1):118-24. PubMed ID: 16403104 [TBL] [Abstract][Full Text] [Related]
30. [Cefotaxime, twenty years later. Observational study in critically ill patients]. Alvarez-Lerma F; Palomar M; Olaechea P; Sierra R; Cerda E; Enferm Infecc Microbiol Clin; 2001 May; 19(5):211-8. PubMed ID: 11446909 [TBL] [Abstract][Full Text] [Related]
31. Cefotaxime: United Kingdom clinical trial results in the treatment of severe infections. Bax RP; Young JP Curr Med Res Opin; 1981; 7(6):401-9. PubMed ID: 6263548 [TBL] [Abstract][Full Text] [Related]
32. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections]. Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209 [TBL] [Abstract][Full Text] [Related]
33. The role of cefotaxime in the treatment of surgical infections. Wittmann DH Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036 [TBL] [Abstract][Full Text] [Related]